The latest

Sensorium Therapeutics Highlights Promising Data on Lead Assets Targeting Anxiety & Epilepsy at Neuroscience 2024

Sensorium Therapeutics Appoints Sam Rasty as Chief Business Officer

Sensorium Therapeutics Expands Board Leadership with Addition of Simba Gill, Ph.D., as Independent Director

Sensorium Therapeutics Announces Appointment of Veteran Biotech Executive Alexandra Glucksmann, Ph.D., as CEO as the Company Progresses Toward the Clinic

Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

Sensorium Therapeutics Appoints Jeffrey M. Brown as Chief Scientific Officer

Boston Business Journal: MGH scientists get $30M to make drugs using natural psychoactives

BioWorld: Sensorium raises $30M in series A round to probe plants, fungi for psychoactive natural products

Endpoints News: Mining from plants and fungi, CNS startup takes leap into psychoactive drugs — complete with $30M to kick things off

BioSpace: Sensorium Scores $30M to Change Risk-Value Proposition in CNS Drug Discovery

Sensorium Therapeutics Closes $30 Million Series A to Transform Mental Health Treatment with Nature-Inspired Psychoactive Medicines